And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, as you know, our treasured signal to daydream about weekend plans. Our agenda kicks off with another installment in our “let’s-see-them-before-they-die” concert series, but then is likely to ease into a series of overdue naps. And what about you? There is a holiday approaching on this side of the pond, so perhaps this is a chance to plan your menu or determine how to decline an unwanted invitation. You could enjoy the great outdoors. Or simply do nothing. Well, whatever your choices, have a grand time. But be safe. Enjoy, and see you soon …
Bratislava, Slovakia, and Milan, Italy, have emerged as front-runners to host the European Medicines Agency after Brexit, the Financial Times informs us. European Union ministers from 27 countries will vote in a secret ballot on Nov. 20 on a new home for the regulator. However, an EMA survey of employees found that more than 70 percent of its staff may leave if the agency is moved to the Slovak capital.
Roche (ROG) won an earlier-than-expected approval from the Food and Drug Administration for its Hemlibra hemophilia A treatment, after a development process dogged by safety issues and a legal spat with Shire (SHPG), PMLive tells us. The drug maker hopes to grab a big chunk of an estimated $7 billion global market that is currently dominated by Shire and Novo Nordisk (NVO). However, its medicine has a black box warning that Hemlibra has been linked to severe blood clots.
May I observe that, though Professor Turner is entitled to a position, few warning letters in my memory were accompanied by a press release, cf US Stem Cell on 28 AUG 2017, followed by a statement by the Commissioner.**
We shall see how this spins out, so to speak.
Comments are closed.